Fat-Derived cell therapy could offer new hope for thumb arthritis
NCT ID NCT05915962
First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study examines nanofat—a processed form of a person's own fat—to see if it could be used as a cell therapy for rhizarthrosis, a common and painful form of thumb osteoarthritis. Researchers will collect fat samples from healthy volunteers and analyze the cells and sterility in the lab. The goal is to understand the biological makeup of nanofat before testing it as a treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Nanofat autograft (emulsified fat tissue containing mesenchymal stromal cells)
- What this could lead to
- If successful, this biological characterization could pave the way for using nanofat as a cell therapy to treat thumb osteoarthritis, potentially reducing pain and improving function without surgery.
- What could go wrong
- This is a very early, small study focused only on lab analysis of the nanofat, not on treating patients. It may not lead to an effective therapy, and the preparation method may not produce consistent results.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
10 people
The number who actually took part.
- Started
-
Jun 2022
- Finished
-
Sep 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
20 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Volunteers, men or women, aged at least 20 to 75 years old. 2. BMI ≥ 20 Kg/m² (in order to have adipose tissue in quantity sufficient) 3. Volunteers who signed an informed consent 4. Hemoglobinemia \> 10g/dl 5. Negative Beta-HCG assay 6. Volunteers benefiting from or affiliated to a social security scheme Exclusion Criteria: 1. Thrombocytopenia \< 150 G/L 2. Thrombocytosis \> 450 G/L 3. Known thrombopathy 4. TP \< 70% 5. APT Patient/Control ratio \> 1.20 6. Anemia \< 10g/dl 7. Taking antiplatelet, aspirin, anti vitamin K dating less than 15 days before inclusion 8. Fever or recent infection (bacterial or viral) dating from less than a month 9. Autoimmune diseases confirmed by questioning, or clinical and/or biological elements (inflammatory assessment: VS, CRP, fibrinogen) and may interfere with the quality of autograft 10. Inflammatory arthritis 11. Microcrystalline Arthritis 12. Immunodeficiency 13. Current or chronic infectious diseases (viral or bacterial) attested by clinical elements and/or biological (inflammatory assessment: ESR, CRP, Fibrinogen) 14. Malignant tumor under treatment or history of malignant tumor 15. BMI \< 20 Kg/m² 16. Contraindication to local anesthesia or surgery 17. Pregnant or breastfeeding women 18. Adults protected by law (under guardianship and guardianship) 19. People participating simultaneously in another research involving the human person 20. Miners 21. Persons staying in a health or social establishment 22. People in an emergency situation 23. Persons deprived of liberty 24. Persons not covered by a social security scheme
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Rhizarthrosis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Privé Paul d'Egine
Champigny-sur-Marne, 94500, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.